NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA on Thursday issued a final local coverage determination for Castle Biosciences' DecisionDx-Melanoma assay, a prognostic test for cutaneous melanoma that helps guide use of sentinel lymph node biopsy (SLNB).
Menu
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Mar
27
Featured Webinar
How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit
Sponsored by
Swift Biosciences
Apr
09
Featured Webinar
Combining AI with Community-Driven Insights: Advanced Diagnosis of Inherited Cardiac Diseases
Sponsored by
Sophia Genetics
Apr
11
Featured Webinar
The 'Dark Matter' of Cancer Genomics: Revealing Undetected Structural Variants in Leukemia
Sponsored by
Bionano Genomics
Apr
17
Sponsored by
Isoplexis
What's Popular?
In Cancer